Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.
Donald A. Richards, MD, PhD
Advertisement
Articles by Donald A. Richards, MD, PhD
Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.
Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.
Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.
Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Dr. Richards on PARP Inhibition in Pancreatic CancerPublished: September 19th 2019 | Updated:
Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic CancerPublished: September 21st 2019 | Updated:
Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic CancerPublished: September 23rd 2019 | Updated:
Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic CancerPublished: September 27th 2019 | Updated:
Dr. Richards on Genetic Testing in Metastatic Pancreatic CancerPublished: October 21st 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5